arrow
Back
A

Adam Brufsky

Harvard University

94H-index
1.0KPaper Count
3.6WCitation Count
Published Papers 350
Publication Date
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
err2026-07-13
err0
PREAI
errNicholas C Turner; Erica L Mayer; Yeon Hee Park; Wolfgang Janni; Cynthia Ma; Massimo Cristofanilli; Giampaolo Bianchini; Kevin Kalinsky; Hiroji Iwata; Stephen Chia; Adam M Brufsky; Peter A Fasching; Zbigniew Nowecki; Javier Pascual; Nuri Karadurmus; Einav Gal-Yam; Wei-Pang Chung; Seock-Ah Im; Alberto Zambelli; Florence Dalenc
errShare
errSave
Multi-modal AI for comprehensive breast cancer prognostication
err2026-05-20
err0
errOAAI
errJan Witowski; Ken G. Zeng; Joseph Cappadona; Jailan Elayoubi; Khalil Choucair; Elena Diana Chiru; Nancy Chan; Young-Joon Kang; Frederick Howard; Irina Ostrovnaya; Carlos Fernandez-Granda; Freya Schnabel; Zoe Steinsnyder; Ugur Ozerdem; Kangning Liu; Waleed Abdulsattar; Yu Zong; Lina Daoud; Rafic Beydoun; Anas M. Saad; Nitya Thakore; Mohammad Sadic; Frank Yeung; Elisa Liu; Theodore Hill; Benjamin Swett; Danielle Rigau; Andrew J. Clayburn; Valerie Speirs; Marcus Vetter; Lina Sojak; Simone Muenst; Daniel Baumhoer; Jia-Wern Pan; Haslina Makmur; Soo-Hwang Teo; Linda M. Pak; Victor Angel; Dovile Zilenaite-Petrulaitiene; Arvydas Laurinavicius; Natalie Klar; Brian D. Piening; Carlo Bifulco; Sun-Young Jun; Jae Pak Yi; Su Hyun Lim; Adam Brufsky; Francisco J. Esteva; Lajos Pusztai; Yann LeCun; Krzysztof J. Geras
errShare
errSave
Biomarker prediction of immunotherapy response in breast cancer: from single markers to multi-omics integration
err2025-12-09
err0
errOAAI
errAli Sanjari Moghaddam; Kit Y. Lu; Elham Nasrollahi; Lovette Oji; Anna Homeniuk; Oyindamola Amosu; Daria Chelysheva; Adam M. Brufsky
errShare
errSave
Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030)
err2025-11-01
err0
PREAI
errNader-Marta, Guilherme; Chu, Xiangying; Mukhopadhyay, Satabhisa; Abramson, Vandana G.; Brufsky, Adam; Stringer-Reasor, Erica Michelle; Dent, Susan Faye; Traina, Tiffany A.; Carey, Lisa A.; Rimawi, Mothaffar F.; Specht, Jennifer M.; Miller, Kathy D.; Santa-Maria, Cesar Augusto; Dasgupta, Tathagata; Kurt, Busem Binboga; Demeo, Michelle; Krop, Ian E.; Tung, Nadine M.; Schnitt, Stuart J.; Tayob, Nabihah; Mayer, Erica L.
errShare
errSave
Correction: Comparative efficacy of first- versus second-line CDK4/6 Inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer
err2025-10-24
err0
errOAAI
errVictoria Lis Ravani; Zahra Bagheri; Adam M. Brufsky; Isabella Michelon; Ruth O’Regan; Maryam Lustberg; Hyo Han; Ming Wang; Seth A. Wander
errShare
errSave
Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy
err2025-10-20
err0
errOAAI
errE.L. Mayer; F.-C. Bidard; Y.H. Park; W. Janni; C. Ma; M. Cristofanilli; H. Iwata; G. Bianchini; K. Kalinsky; S. Chia; A. Brufsky; P.A. Fasching; Z. Nowecki; S.-C. Chen; J. Pascual; L. Moreau; M. Ruiz-Borrego; A. Shai; N. Karadurmus; J.H. Sohn; Y. Zhu; I. Leddin; M.S. Miralles; C.H. Bartlett; N. Turner
errShare
errSave
Real-world progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR-positive/HER2-negative metastatic breast cancer in United States routine clinical practice
err2025-09-01
err0
errOAAI
errH.S. Rugo; R.M. Layman; F. Lynce; X. Liu; B. Li; L. McRoy; A.B. Cohen; M. Estevez; G. Curigliano; A. Brufsky
errShare
errSave
Finding the right tool for the specific task: navigating RWE tools and checklists
err2025-09-01
err0
errOAAI
errRichard Willke; Paul Cottu; Andrew Briggs; Uwe Siebert; Connie Chen; Beata Korytowsky; Julien Heidt; Meghan Renfrow; Kate Lovett; Adam Brufsky
errShare
errSave
Palbociclib Treatment in Patients with HR+/HER2− Advanced or Metastatic Breast Cancer and Visceral Metastasis: A Systematic Literature Review
err2025-08-28
err0
errOAAI
errJulia C. Radosa; Sara López-Tarruella Cobo; Johanna Dzieran; Esther Glastetter; Connie Chen; Melissa Lingohr-Smith; Vinay Pasupuleti; Adam Brufsky
errShare
errSave
Real-world effectiveness and safety of CDK4/6i in elderly and BIPOC patients with HR+/HER2- advanced/metastatic breast cancer: an updated systematic literature review
err2025-08-15
err0
errOAAI
errNadia Harbeck; Adam Brufsky; Chloe Grace Rose; Beata Korytowsky; Connie Chen; Krista Tantakoun; Endri Jazexhi; Do Hoang Vien Nguyen; Meaghan Bartlett; Imtiaz A. Samjoo; Timothy Pluard
errShare
errSave
MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world data
err2025-08-11
err0
errOAAI
errAdam M Brufsky; Kent F Hoskins; Henry J Conter; Pond Kelemen; Mehran Habibi; Laila Samian; Rakshanda L Rahman; Laura Lee; Eduardo C Dias; Regina Hampton; Beth A Sieling; Cynthia R Osborne; Eric Brown; Jailan A Elayoubi; Priyanka Sharma; Jayanthi Ramadurai; Laurie Matt-Amaral; Alfredo A Santillan; Sasha Davis; Philip Albaneze; Harshini Ramaswamy; Nicole Chmielewski-Stivers; Andrea Menicucci; William Audeh; Pat Whitworth; Nathalie Johnson; Joyce O’Shaughnessy
errShare
errSave
Response to the letter Re: Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2− metastatic breast cancer in the US real-world setting
err2025-07-01
err0
PREAI
errH.S. Rugo; R.M. Layman; F. Lynce; X. Liu; B. Li; L. McRoy; A.B. Cohen; M. Estevez; G. Curigliano; A. Brufsky
errShare
errSave
Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2− early breast cancer: a United States Electronic Health Records database analysis
err2025-06-01
err0
errOAAI
errP. Tarantino; H.S. Rugo; G. Curigliano; J.A. O’Shaughnessy; W. Janni; K. Jhaveri; J. Mouabbi; A. Brufsky; E. Hamilton; R. O’Regan; L. Santarsiero; M. Akdere; F. Ye; A. Scotchmer; S.L. Graff
errShare
errSave
Real-World Evidence Acceptability and Use in Breast Cancer Treatment Decision-Making in the United States: Call-to-Action from a Multidisciplinary Think Tank
err2025-05-12
err0
errOAAI
errKhozin, S; Dreyer, NA; Galante, D; Liu, RY; Neumann, P; Nussbaum, N; O'Shaughnessy, J; Patt, D; Rimawi, M; Rugo, H; Tolaney, SM; Weiss, M; Brufsky, A
errShare
errSave
Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2-Metastatic Breast Cancer
err2025-03-27
err0
errOAAI
errBrufsky, Adam M.; Sandin, Rickard; Stergiopoulos, Stella; Chen, Connie; Karanth, Siddharth; Li, Benjamin; Esterberg, Elizabeth; Makari, Doris; Candrilli, Sean D.; Goyal, Ravi K.; Rugo, Hope S.
errShare
errSave